Invion secures funding for development programs

Invion Limited (ASX: $IVX) has secured a minimum of $2.4 million and up to $6.8 million in funding through a Share Subscription Agreement and Share Purchase Agreement with Lind Global Fund II, LP, managed by The Lind Partners. The funding will provide Invion with greater financial flexibility as it pursues multiple development programs across a range of cancers and infectious diseases.

Chairman and CEO's perspective on the funding

Chairman and CEO of Invion, Thian Chew, expressed excitement about the partnership with Lind, highlighting the potential of their technology in treating various cancers and infectious diseases. The capital investment is expected to provide resources and flexibility to advance their development programs, including the Phase I/II non-melanoma skin cancer trial.

Summary of funding and outlook

Invion (ASX: $IVX) has secured a significant investment from Lind Partners, providing a financial boost for the company's development programs in cancer and infectious diseases. The funding, ranging from $2.4 million to $6.8 million, will support the advancement of their technology and treatment trials. With the backing of Lind, Invion aims to make progress in its pipeline of development programs, signaling a positive outlook for the company's research and development initiatives.